X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2390) 2390
Publication (298) 298
Book Review (43) 43
Book Chapter (38) 38
Magazine Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hepatitis c virus (1305) 1305
index medicus (1213) 1213
hepatitis c (1173) 1173
direct-acting antivirals (1031) 1031
humans (991) 991
gastroenterology & hepatology (713) 713
antiviral agents - therapeutic use (686) 686
ribavirin (592) 592
antiviral agents (588) 588
hepatitis c, chronic - drug therapy (564) 564
hepatitis (545) 545
interferon (516) 516
sofosbuvir (470) 470
hcv (421) 421
male (407) 407
sustained virological response (401) 401
health aspects (398) 398
female (378) 378
hepacivirus - genetics (374) 374
infectious diseases (371) 371
middle aged (362) 362
genotype (359) 359
cirrhosis (339) 339
hepacivirus - drug effects (339) 339
therapy (327) 327
virus-infection (322) 322
infection (314) 314
treatment outcome (314) 314
drug therapy, combination (312) 312
direct-acting antiviral (303) 303
virus diseases (297) 297
direct-acting antiviral agents (290) 290
hepatitis c - drug therapy (287) 287
direct acting antivirals (285) 285
liver (274) 274
virology (255) 255
patients (251) 251
infections (249) 249
adult (248) 248
analysis (247) 247
care and treatment (244) 244
liver cirrhosis (243) 243
biological response modifiers (239) 239
drug therapy (239) 239
genotype 1 infection (232) 232
aged (228) 228
viruses (224) 224
sustained virologic response (220) 220
chronic hepatitis c (215) 215
hepatitis c, chronic - virology (210) 210
pharmacology & pharmacy (209) 209
digestive system diseases (189) 189
hiv (186) 186
ribavirin - therapeutic use (185) 185
hepatocellular carcinoma (184) 184
pegylated interferon (181) 181
antiviral agents - administration & dosage (180) 180
antiviral agents - adverse effects (180) 180
daclatasvir (179) 179
treatment-naive patients (176) 176
genotype 1 (172) 172
ledipasvir (170) 170
protease inhibitors (169) 169
telaprevir (167) 167
hcv infection (165) 165
immunology (160) 160
hepatology (158) 158
prevalence (158) 158
hepatitis-c virus (157) 157
genotypes (155) 155
hepatitis c, chronic - complications (155) 155
medical research (154) 154
antiviral agents - pharmacology (152) 152
plus ribavirin (151) 151
gastroenterology and hepatology (150) 150
genetic aspects (146) 146
liver transplantation (145) 145
efficacy (144) 144
medicine, experimental (142) 142
medicine & public health (141) 141
direct‐acting antivirals (137) 137
fibrosis (136) 136
safety (135) 135
genotype & phenotype (134) 134
hepatocellular-carcinoma (134) 134
microbiology (134) 134
risk factors (134) 134
chronic hepatitis-c (123) 123
transplantation (123) 123
antiviral therapy (120) 120
epidemiology (120) 120
boceprevir (118) 118
simeprevir (118) 118
medicine, general & internal (117) 117
liver diseases (115) 115
recurrence (115) 115
treatment-naive (115) 115
mortality (114) 114
review (114) 114
hepatitis c - virology (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2238) 2238
Korean (62) 62
Spanish (42) 42
Hungarian (24) 24
Japanese (17) 17
French (16) 16
German (16) 16
Russian (9) 9
Chinese (2) 2
Italian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 07/2017, Volume 37, Issue 7, pp. 974 - 981
Background & Aims The aim of this study was to assess the efficacy and safety of direct‐acting antivirals (DAA)‐based antiviral therapies for HCV patients with... 
direct‐acting antiviral | stage 4‐5 chronic kidney disease | hepatitis C virus infection | meta‐analysis | meta-analysis | direct-acting antiviral | stage 4-5 chronic kidney disease | ASUNAPREVIR | RENAL-DISEASE | COMBINATION | DIALYSIS PATIENTS | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | HEMODIALYSIS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Renal Insufficiency, Chronic - complications | Time Factors | Adult | Female | Hepatitis C - complications | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Odds Ratio | Kidney - physiopathology | Hepacivirus - drug effects | Severity of Illness Index | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hepatitis C - diagnosis | Antiviral Agents - adverse effects | Hepatitis C - virology | Hepacivirus - growth & development | Aged | Sustained Virologic Response | Antiviral agents | Care and treatment | Chronic kidney failure | Hepatitis C virus | Health aspects | Analysis | Renal function | Ritonavir | Viruses | Disease control | Patients | Incidence | Confidence intervals | Hepatitis | Renal failure | Dialysis | Libraries | Kidney diseases | Safety | Hepatitis C | Kidney transplantation
Journal Article
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 01/2019, Volume 31, Issue 1, pp. 75 - 79
Journal Article
HIV Medicine, ISSN 1464-2662, 04/2017, Volume 18, Issue 4, pp. 284 - 291
Journal Article
by Boerekamps, Anne and Newsum, Astrid M and Smit, Colette and Arends, Joop E and Richter, Clemens and Reiss, Peter and Rijnders, Bart J.A and Brinkman, Kees and Van Der Valk, Marc and Geerlings, S.E and Godfried, M.H and Goorhuis, A and Hovius, J.W and Van Der Meer, J.T.M and Kuijpers, T.W and Nellen, F.J.B and Van Der Poll, D.T and Prins, J.M and Van Vugt, H.J.M and Wiersinga, W.J and Wit, F.W.M.N and Van Duinen, M and Van Eden, J and Van Hes, A.M.H and Mutschelknauss, M and Nobel, H.E and Pijnappel, F.J.J and Weijsenfeld, A.M and Jurriaans, S and Back, N.K.T and Zaaijer, H.L and Berkhout, B and Cornelissen, M.T.E and Schinkel, C.J and Wolthers, K.C and Van Den Berge, M and Stegeman, A and Baas, S and Hage De Looff, L and Wintermans, B and Veenemans, J and Pronk, M.J.H and Ammerlaan, H.S.M and De Munnik, E.S and Jansz, A.R and Tjhie, J and Wegdam, M.C.A and Deiman, B and Scharnhorst, V and Van Eeden, A and Brokking, W and Groot, M and Elsenburg, L.J.M and Damen, M and Kwa, I.S and Van Kasteren, M.E.E and Brouwer, A.E and Van Erve, R and De Kruijf-Van De Wiel, B.A.F.M and Keelan-Pfaf, S and Van Der Ven, B and De Kruijf-Van De Wiel, B.A.F.M and Van Der Ven, B and Buiting, A.G.M and Kabel, P.J and Versteeg, D and Van Der Ende, M.E and Bax, H.I and Van Gorp, E.C.M and Nouwen, J.L and Schurink, C.A.M and Verbon, A and De Vries-Sluijs, T.E.M.S and De Jong-Peltenburg, N.C and Bassant, N and Van Beek, J.E.A and Vriesde, M and Van Zonneveld, L.M and Van Den Berg-Cameron, H.J and De Groot, J and De Zeeuw-De Man, M and Boucher, C.A.B and Koopmans, M.P.G and Van Kampen, J.J.A and Pas, S.D and Branger, J and Rijkeboer-Mes, A and Duijf-Van De Ven, C.J.H.M and Schippers, E.F and Van Nieuwkoop, C and Van IJperen, J.M and Geilings, J and Van Der Hut, G and Van Burgel, N.D and Leyten, E.M.S and Gelinck, L.B.S and Van Hartingsveld, A.Y and Meerkerk, C and Wildenbeest, G.S and Heikens, E and ... and Netherlands ATHENA HIV Observation and NVHB-SHM Hepatitis Working Grp and NVHB-SHM Hepatitis Working Group and the Netherlands ATHENA HIV Observational Cohort
Clinical Infectious Diseases, ISSN 1058-4838, 05/2018, Volume 66, Issue 9, pp. 1352 - 1359
Background. The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C... 
Treatment uptake | HIV/HCV coinfection | Direct-acting antivirals | treatment uptake | INFECTIOUS DISEASES | EFFICACY | SAFETY | SEX | MICROBIOLOGY | IMMUNOLOGY | direct-acting antivirals | INDIVIDUALS | HIV | REINFECTION | MEN | INFECTION | COHORT | AMSTERDAM
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2017, Volume 178, Issue 1, pp. 130 - 136
Journal Article